The Breztri Aerosphere from AstraZeneca plc - triple therapy aims at severe COPD

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-27, 04:50. Details in the imprint.

When Breztri Aerosphere from AstraZeneca plc rattles softly in the patient’s hand, the small metal canister and plastic body feel surprisingly solid for something that controls breathlessness. One press, a cool aerosol cloud, then a slow inhale that can decide how the next hours feel.

What Breztri actually is

Breztri Aerosphere is a fixed-dose triple inhaler that combines the inhaled corticosteroid budesonide, the long-acting muscarinic antagonist glycopyrronium and the long-acting beta-agonist formoterol. In plain language, it puts anti-inflammatory and dual bronchodilation into one device for adults with chronic obstructive pulmonary disease.

The pressurized metered-dose inhaler uses AstraZeneca’s Aerosphere formulation, which suspends the active ingredients so they distribute evenly with each actuation. That consistency matters when a patient with severe COPD counts on exactly two puffs twice a day rather than juggling several separate inhalers.

How it is used day to day

In routine practice, pulmonologists usually prescribe Breztri for patients whose COPD remains uncontrolled on dual therapy or who suffered exacerbations despite long-acting bronchodilators. The recommended regimen is maintenance, not rescue, so patients build it into the morning-and-evening bathroom routine next to the toothbrush.

For many, the ritual is simple but tactile: shake, exhale, close lips around the mouthpiece, press and inhale slowly, hold the breath, then repeat. Nurses often stress that slow inhalation is key, because fast, shallow puffs waste the dose in the throat instead of reaching the lungs.

Where Breztri stands in guidelines

Respiratory specialists such as Professor Klaus Rabe in Germany and Dr. Fernando Martinez in the US describe triple therapy inhalers like Breztri as an option for patients with frequent COPD exacerbations despite optimized dual treatment. They generally reference international GOLD guideline steps when escalating to this level.

The drug secured approvals first in Japan and then in major markets including the EU and US for adults with COPD who require maintenance therapy. Payers often position it as a step-up option when exacerbation history and symptom burden justify higher drug costs and more intense anti-inflammatory treatment.

Evidence base and limitations

Pivotal trials compared Breztri against dual combinations and reported reductions in annual exacerbation rates in certain high-risk COPD populations. Effect sizes varied across studies, but the general pattern supported triple therapy as a way to cut moderate and severe flare-ups.

However, the inhaler is not indicated for asthma or for acute bronchospasm, and it does not reverse structural lung damage. Patients still need rescue bronchodilators on hand, and physicians monitor for class-typical side effects such as oral candidiasis, dry mouth, tremor or cardiovascular signals.

How it feels for patients

Patients often notice the slightly chemical taste of the aerosol on the tongue, followed by a faint cold sensation down the throat as the particles travel into the chest. Some describe a quiet reassurance when the wheeze loosens over minutes and the next flight of stairs feels less daunting.

Adherence is another story. Compared with dry powder inhalers, the metered-dose format demands coordination. Respiratory nurse specialists spend time watching patients use Breztri, correcting rushed inhalations, and wiping the mouthpiece to prevent residue that can make the plastic feel rough against the lips.

Pricing and availability

Breztri is a prescription-only maintenance therapy that sits firmly in the specialist drug budget. List prices differ between the United States, Europe and emerging markets, and the real cost to patients depends on local reimbursement, co-pay caps and country-specific negotiations.

In Germany, availability runs through pulmonologists and specialized pharmacies rather than supermarket counters. In AstraZeneca’s home base in the United Kingdom, COPD patients usually access the inhaler through NHS respiratory clinics when guideline criteria for triple therapy are met.

Why AstraZeneca cares about it

For AstraZeneca CEO Pascal Soriot, the respiratory and immunology franchise is a strategic pillar next to oncology and cardiovascular drugs. Breztri contributes recurring revenue in a disease area with high chronic prevalence and a constant flow of newly diagnosed patients.

Analysts therefore watch prescription data for the triple inhaler as one indicator of how the company holds its ground against rivals offering similar combinations. Competition pressures discounts, but a simple two-puffs-twice-daily regimen wrapped in one device can still be a practical differentiator in clinics.

Context for the AstraZeneca share price

Respiratory medicines like Breztri are only part of the broader AstraZeneca story, which today is dominated by oncology, rare disease and cardiovascular launches. For stock market traders, the revenue contribution from this COPD triple therapy is one of several levers that can influence medium-term expectations for AstraZeneca shares on the London Stock Exchange.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.